Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of Three New International Patents for

Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With
Issuance of Three New International Patents for Microcyn(R) Technology

PETALUMA, Calif., April 4, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in over 20
countries, today announced the issuance of three new international patents for
the company's flagship technology, Microcyn®. These include a Chinese patent
for treatment of second- and third-degree burns, and two Mexican patents, the
first for treatment of skin ulcers and the second for treatment of second- and
third-degree burns as well.

Bruce Thornton, executive vice president of Oculus said: "Our intellectual
property portfolio is growing and is perfectly timed with our international
growth. Our Microcyn-based products are now commercialized in more than twenty
countries around the globe with a target of thirty-plus by year's end. The
empirical evidence documenting Microcyn's efficacy in the treatment of both
burns and ulcers is highly compelling. These new patents will further fortify
our marketing efforts for those indications in these regions."

The latest-issued patents join an intellectual property estate (either owned
or licensed to Oculus) that now includes 35 issued patents (five in the United
States, 12 registered in the E.U., and 18 other foreign patents) as well 109
pending applications (including U.S. provisional applications) directed to
chemical compositions, apparatuses, methods of manufacturing and therapeutic
uses.

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in over 20
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets—while raising the
standard of patient care and lowering overall healthcare costs. The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found at
www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and future financial
performance. These forward-looking statements are identified by the use of
words such as "growing," "fortify" and "timed," among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company's business that could cause actual
results to vary, including such risks that regulatory clinical and guideline
developments may change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
        
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
 
Press spacebar to pause and continue. Press esc to stop.